Technical Analysis for AYTU - Aytu BioScience, Inc.

Grade Last Price % Change Price Change
D 2.85 -2.40% -0.07
AYTU closed down 2.4 percent on Monday, July 1, 2024, on 1.23 times normal volume. It was able to bounce off of its 200 day moving average, an important long-term support line. The price action carved out a bullish hammer (or hammer-like) candlestick pattern. That may indicate an upside reversal. Look for price to trade above the high of the hammer for confirmation.
1 Watcher
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
200 DMA Support Bullish 0.00%
Hammer Candlestick Bullish 0.00%
Outside Day Range Expansion -2.40%
NR7 Range Contraction -0.35%
Narrow Range Bar Range Contraction -0.35%
180 Bearish Setup Bearish Swing Setup -1.04%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.68%
NR7 Range Contraction -4.68%
Up 3 Days in a Row Strength -4.68%
Gapped Up Strength -3.39%

   Recent Intraday Alerts

Alert Time
200 DMA Support about 8 hours ago
60 Minute Opening Range Breakdown about 8 hours ago
1.5x Volume Pace about 8 hours ago
Down 5% about 8 hours ago
Down 3% about 8 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aytu BioScience, Inc. Description

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company's pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men. The Company, through its wholly-owned subsidiary Nuelle, Inc., is focused on women’s sexual wellbeing and intimacy.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Organ Systems Alcohol Prostate Cancer Urology In Vitro Hormones Fertility Ketones Estrogen Imaging Agent Infertility Testosterone Urinary Tract Infection In Vitro Diagnostic Device Androstanes Company's Pipeline Male Infertility Urinary Tract Infections

Is AYTU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 3.5
52 Week Low 1.52
Average Volume 21,519
200-Day Moving Average 2.81
50-Day Moving Average 3.01
20-Day Moving Average 2.97
10-Day Moving Average 2.88
Average True Range 0.14
RSI (14) 42.86
ADX 12.39
+DI 13.42
-DI 19.02
Chandelier Exit (Long, 3 ATRs) 2.81
Chandelier Exit (Short, 3 ATRs) 3.17
Upper Bollinger Bands 3.24
Lower Bollinger Band 2.70
Percent B (%b) 0.28
BandWidth 18.25
MACD Line -0.05
MACD Signal Line -0.05
MACD Histogram -0.0052
Fundamentals Value
Market Cap 15.87 Million
Num Shares 5.57 Million
EPS -6.31
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 0.16
Price-to-Book 0.50
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.08
Resistance 3 (R3) 3.08 2.99 3.04
Resistance 2 (R2) 2.99 2.93 2.99 3.03
Resistance 1 (R1) 2.92 2.89 2.88 2.93 3.02
Pivot Point 2.84 2.84 2.81 2.84 2.84
Support 1 (S1) 2.77 2.78 2.72 2.77 2.68
Support 2 (S2) 2.68 2.74 2.68 2.67
Support 3 (S3) 2.61 2.68 2.66
Support 4 (S4) 2.62